Advertisment

Addressing Racial Bias in Pulse Oximeters: A Call for Swift Action and Regulatory Oversight

author-image
Dr. Jessica Nelson
New Update
NULL

Addressing Racial Bias in Pulse Oximeters: A Call for Swift Action and Regulatory Oversight

Advertisment

In a recent meeting held by the U.S. Food and Drug Administration (FDA) advisory panel, advocates and experts expressed their concerns over the lack of swift action to ensure the effectiveness of pulse oximeters across diverse patient populations. The meeting served as a platform for highlighting the pressing need for regulatory oversight of medical devices and their impact on patient care.

Advertisment

Understanding the Issue

Pulse oximeters, which are widely used in healthcare settings to measure oxygen saturation levels in blood, have come under scrutiny for potentially providing less accurate readings in individuals with darker skin tones. Studies have shown that these devices may overestimate oxygen saturation in people with dark skin, potentially leading to delayed or inadequate care. This issue was the central focus of the FDA advisory panel meeting, held on February 2, 2024.

The FDA’s Approach

Advertisment

The FDA is making efforts to improve the quality of premarket studies and associated methods used to evaluate the performance of pulse oximeters. The agency is considering skin pigmentation and patient-reported race and ethnicity in these evaluations. The advisory panel meeting discussed potential approaches, including an update to clinical trial requirements to include more diverse groups of patients.

Proposed Solutions

The FDA advisory panel recommended new standards for pulse oximeters. These include conducting larger and more diverse clinical trials, using the Monk Skin Tone scale and Individual Typology Angle at the sensor site to measure skin pigmentation, and considering non-disparate performance requirements. There were also discussions about whether over-the-counter pulse oximeters should meet the same requirements as prescription use devices.

Advertisment

Feedback from the Advisory Panel

The advisory panel gave high marks to the FDA's latest attempt to improve the accuracy of pulse oximeters in darker-skinned patients. However, concerns were raised about the size of the trial and the acceptable boundaries for variance in oxygen measurements. The panel also discussed the need for evaluating how pulse oximeters perform over time for different skin tones.

Testimonies from Patients

Advertisment

Patients shared their experiences with inaccurate readings due to their skin color during the meeting, emphasizing the need for improvement in pulse oximeter technology. These testimonies underscored the importance of addressing this issue swiftly and effectively.

Moving Forward

The testimonies and discussions from the advisory panel meeting raise important questions about the regulatory oversight of medical devices and their impact on patient care. It is evident that swift action is needed to ensure that pulse oximeters and other medical devices work effectively in all patients, regardless of skin pigmentation or ethnicity. The proposed changes and recommendations from the advisory panel could serve as a significant step towards achieving this goal.

Advertisment
Chat with Dr. Medriva !